| Imatinib treatment: specific issues related to safety, fertility, and pregnancy. | |
| | |
MedLine Citation:
|
PMID: 12783371 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Imatinib (Gleevec) (formerly STI571) has demonstrated high levels of efficacy in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) and has been used in more than 12,000 patients participating in clinical trials. Experience from clinical trials with imatinib has largely demonstrated the drug to be well tolerated in humans. Common side effects, usually manageable, include nausea, rash, superficial edema, myelosuppression, muscle cramps, and elevated liver transaminases. With longer follow-up and with further experience with the treatment of patients outside of clinical trials, we are able to report on rarer toxicities, the identification of certain predictors of common toxicities, and the clinical experience with male fertility and pregnancy outcomes. |
| | |
Authors:
|
Martee L Hensley; John M Ford |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in hematology Volume: 40 ISSN: 0037-1963 ISO Abbreviation: Semin. Hematol. Publication Date: 2003 Apr |
Date Detail:
|
Created Date: 2003-06-03 Completed Date: 2004-03-04 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0404514 Medline TA: Semin Hematol Country: United States |
Other Details:
|
Languages: eng Pagination: 21-5 Citation Subset: IM |
Copyright Information:
|
Copyright 2003 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Oncology Clinical Research, Novartis Pharmaceuticals, Basel, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Female Fertility / drug effects* Hematologic Neoplasms / complications, drug therapy, pathology Humans Male Piperazines / adverse effects*, therapeutic use Pregnancy Pregnancy Outcome* Pyrimidines / adverse effects*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Imatinib: a targeted clinical drug development.
Next Document: Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.